Valor202020212022202320242025TTMGastos comerciales, generales y administrativos354.32 M186.35 M150.29 M232.62 M267.47 M393.87 M393.87 MInvestigación y desarrollo531 M638.2 M———915.62 M—Beneficio operativo-172.08 M-30.19 M-410.19 M-353.73 M-475.08 M-381.68 M-381.69 MTotal de ingresos no operativos47.04 M19.01 M10.72 M101.38 M105.48 M92.63 M92.63 MGastos por intereses, netos de intereses capitalizados44.99 M9.35 M8.12 M12.66 M16.99 M17.26 M17.26 MIngresos no operativos, una vez deducidos los gastos por intereses2.11 M10.8 M9.88 M74.47 M87.14 M90.72 M90.72 MIngresos/gastos extraordinarios-62 K-1.13 M-7.27 M14.26 M1.34 M-15.36 M-15.36 MBeneficio antes de impuestos-170.03 M-29.15 M-257.99 M-333.96 M-460.07 M-379.6 M-379.6 MParticipación en los beneficios———————Impuestos316.73 M-551 K11.74 M32.32 M-6.17 M1.79 M1.79 MParticipación minoritaria-35.48 M00————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-451.29 M-28.6 M-269.72 M-366.29 M-453.9 M-381.39 M-381.39 MOperaciones suspendidas———————Beneficio neto-451.29 M-28.6 M-269.72 M-366.29 M-453.9 M-381.39 M-381.39 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-451.49 M-28.6 M-269.72 M-366.29 M-453.9 M-381.39 M-381.39 MBeneficio básico por acción-3.23-0.2-1.9-2.56-3.04-2.38—Beneficio por acción diluido-3.23-0.2-1.9-2.56-3.04-2.38—Número medio de acciones ordinarias139.61 M141.02 M141.85 M143.19 M149.51 M160.01 M—Acciones diluidas139.61 M141.02 M141.85 M143.19 M149.51 M160.01 M—EBITDA-106.43 M10.33 M-380.69 M-363.43 M-494.17 M-386.06 M-382.5 MEBIT-172.08 M-30.19 M-410.19 M-353.73 M-475.08 M-381.68 M-381.69 MCosto de los ingresos11.95 M10.84 M14.12 M9.13 M11.21 M15.91 M15.91 MOtros costes de producción00—————Amortización y depreciación (flujo de caja)65.65 M40.52 M29.5 M-9.7 M-19.09 M-4.38 M-817 K
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.